The unique properties of contemporary targeted drugs pose major challenges for the development of anticancer therapy, necessitating modification of traditional clinical trial designs. This article discusses some of the strategies employed to evaluate these agents in the phase I to 111 setting, citing examples of some recently tested targeted agents to illustrate the advantages and disadvantages of various approaches.
机构:
Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USAFred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA
Hoering, Antje
LeBlanc, Mike
论文数: 0引用数: 0
h-index: 0
机构:
Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USAFred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA
LeBlanc, Mike
Crowley, John J.
论文数: 0引用数: 0
h-index: 0
机构:
Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USAFred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA
机构:
Univ Calif Berkeley, Forum Collaborat HIV Res, Sch Publ Hlth, Washington, DC 20037 USAUniv Calif Berkeley, Forum Collaborat HIV Res, Sch Publ Hlth, Washington, DC 20037 USA
Mani, Nina
Miller, Veronica
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Berkeley, Forum Collaborat HIV Res, Sch Publ Hlth, Washington, DC 20037 USAUniv Calif Berkeley, Forum Collaborat HIV Res, Sch Publ Hlth, Washington, DC 20037 USA